Millipore Sigma Vibrant Logo

05-23-0101 Angiotensin II, Human - CAS 4474-91-3 - Calbiochem

Plays an important role in the regulation of blood pressure.

Ficha de dados de segurança do material (FDSM) ou ficha de segurança do material (FSM), certificado de análise (CA) e certificado de qualidade (CQ), dossiês e outros documentos disponíveis.

Sinônimos: DRVYIHPF

Primary Target: adenylate cyclase activity
View Products on Sigmaaldrich.com
05-23-0101
Ver preços e disponibilidade

Panorama geral

Replacement Information

Tabela com principais espec.

CAS #Empirical Formula
4474-91-3C₅₀H₇₁N₁₃O₁₂

Preço e Disponibilidade

Número de catálogo DisponibilidadeEmbalagem Qtde/Emb. Preço Quantidade
05-23-0101-25MG
Verificando a disponibilidade...
—
Disponibilidade limitada Disponibilidade limitada
Insira quantidade 
Descontinuado
Quantidades limitadas disponíveis
Disponibilidade a ser confirmada
    Restante: será informado
      Restante: será informado
      Vai informar
      Contatar o serviço de atendimento ao cliente
      Contact Customer Service

      		 Frasco de vidro 25 mg
      Recuperando preço...
      O preço não pôde ser recuperado
      Quantidade mínima necessária para ser múltipla de
      Maximum Quantity is
      Após finalização do pedido Mais informações
      Você salvou ()
       
      —
      Solicitar preço
      		 —
      Description
      OverviewPlays an important role in the regulation of blood pressure. Stimulates the release of aldosterone from the adrenal gland. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Also elicits an increase in voltage-dependent delayed rectifier K+ current in neurons. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates p60c-src as well as ERK1/2, JNK, and p38 MAP Kinase in vascular smooth muscle cells.
      Catalogue Number05-23-0101
      Brand Family Calbiochem®
      SynonymsDRVYIHPF
      References
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Product Information
      CAS number4474-91-3
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₅₀H₇₁N₁₃O₁₂
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Hygroscopic Hygroscopic
      ReversibleN
      Sold on the basis of peptide contentY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetadenylate cyclase activity
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide ContentY
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSBW2165000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de catálogo GTIN
      05-23-0101-25MG 04055977206913

      Documentation

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem MSDS

      Título

      Ficha de Segurança de Produtos (MSDS) 

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem Certificados de análise

      TítuloNúmero do lote
      05-23-0101

      Referências

      Visão geral de referência
      Zhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Ficha de dados

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-May-2008 JSW
      SynonymsDRVYIHPF
      DescriptionFunctions in blood pressure maintenance. Stimulates the release of aldosterone from the adrenal gland. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates pp60c-src in vascular smooth muscle cells. Inhibits adenylate cyclase activity in spontaneously hypertensive rats.
      FormWhite to off-white solid
      CAS number4474-91-3
      RTECSBW2165000
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Purity≥98% by HPLC
      Solubility5% acetic acid (1 mg/ml) or H₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Toxicity Standard Handling
      Merck USA index14 651
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.